A new class of agents for estrogen-receptor-positive breast cancer

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Expert Review of Clinical Pharmacology

• Publication date

  2018-03-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17512433.2018.1439736PMID 29439601
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Review of Fulvestrant in Breast Cancer

  2017cited by this paper
• Abstract 4148: Novel ERX-11 and CDK4/6 inhibitor combination therapy for treating therapy resistant breast cancer

  2017cited by this paper
• Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers

  2017influential reference
• Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.

  2016cited by this paper
• Optimal management of hormone receptor positive metastatic breast cancer in 2016

  2015cited by this paper
• Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State

  2015cited by this paper
• Mechanisms of aromatase inhibitor resistance

  2015cited by this paper
• Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer

  2014cited by this paper
• Estrogen receptor coregulators and pioneer factors: the orchestrators of mammary gland cell fate and development

  2014influential reference
• PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.

  2014cited by this paper
• A good drug made better: the fulvestrant dose-response story.

  2014cited by this paper
• D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.

  2013cited by this paper
• Activating ESR1 mutations in hormone-resistant metastatic breast cancer

  2013cited by this paper
• Treatment of estrogen receptor-positive breast cancer.

  2013cited by this paper
• ESR1 ligand binding domain mutations in hormone-resistant breast cancer

  2013cited by this paper
• Sex hormones and breast cancer risk and prognosis.

  2013cited by this paper
• AIB1:ERα Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor–Resistant Breast Cancer Cells

  2012cited by this paper
• Nuclear receptor coregulators: modulators of pathology and therapeutic targets

  2012cited by this paper
• Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study

  2012cited by this paper
• The Dynamic Structure of the Estrogen Receptor

  2011cited by this paper
• The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype

  2010cited by this paper
• Nuclear receptor coregulators in cancer biology.

  2009cited by this paper
• Biological determinants of endocrine resistance in breast cancer

  2009cited by this paper
• Challenges in defining predictive markers for response to endocrine therapy in breast cancer.

  2009cited by this paper
• Nuclear receptor coregulators and human disease.

  2008cited by this paper
• Molecular biology. Little molecules with big goals.

  2006cited by this paper
• Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

  2006cited by this paper
• Little Molecules with Big Goals

  2006cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Measurement of steroid hormone receptors in breast cancer patients on tamoxifen

  2004cited by this paper
• Mechanisms of tamoxifen resistance.

  2004cited by this paper
• Fulvestrant versus anastrazole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials

  2004cited by this paper
• Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women

  2003cited by this paper
• Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen.

  2003cited by this paper
• Endocrine-resistant breast cancer: Underlying mechanisms and strategies for overcoming resistance

  2003cited by this paper
• Connections and Regulation of the Human Estrogen Receptor

  2002cited by this paper
• Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue

  2001cited by this paper
• Mechanisms of estrogen action.

  2001cited by this paper
• ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics.

  2000cited by this paper
• The structure of the nuclear hormone receptors.

  1999cited by this paper
• Treatment of breast cancer.

  1998cited by this paper
• A signature motif in transcriptional co-activators mediates binding to nuclear receptors

  1997cited by this paper
• Transcription activation by estrogen and progesterone receptors.

  1991cited by this paper
• [Treatment of breast cancer].

  1971cited by this paper

• Computer-Aided Ligand Discovery for Estrogen Receptor Alpha

  2020cites this paper
• Biology and Genetics of Breast Cancer

  2019cites this paper